Project Grant K99CA304511
Award Date
7/7/25
Completion Date
6/30/27
Dollars Obligated
$186K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $571,271 to the University of Texas Health Science Center at Houston to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research aims to synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate that can selectively deliver the microtubule inhibitor cryptophycin to MCRPC tumors. The project will...
This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,967,999.00 to The Regents of the University of California, San Francisco (UCSF) to develop a CD46 targeted antibody fragment radiopharmaceutical therapy for the treatment of prostate cancer. The award period runs from July 1, 2025 to June 30, 2028. UCSF, a leading academic medical and research institution, will leverage its expertise in biomedical...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research aimed at overcoming resistance to radiopharmaceutical therapy (RPT) in prostate cancer. The $404,972 award, effective August 1, 2025 through July 31, 2027, will enable researchers at the University of California, Los Angeles (UCLA) to investigate how the tumor microenvironment, specifically the enzyme ENPP1, can limit the immune-activating effects of PSMA-targeted RPT....
This Project Grant award, valued at $678,101, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Regents of the University of California, San Francisco (UCSF). The funding supports a 5-year research project to develop a novel radioimmunotherapy targeting the active conformation of integrin beta-2 as a potential best-in-class treatment for acute myeloid leukemia (AML). The key objectives are to: 1) evaluate the preclinical efficacy...
This Project Grant award of $676,567.00 was provided by the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), to The Regents of the University of California, San Francisco (UCSF). The award will fund a multi-year research project to systematically test a transforming growth factor beta (TGFB) targeted theranostic radiopharmaceutical therapy approach across preclinical cancer models. The research aims to assess the biological effectiveness of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Cancer Targeted Technology LLC to develop and validate a novel PSMA-targeted small molecule prodrug called CTT2274 for the treatment of advanced prostate cancer. The key product being developed under this award is CTT2274, which utilizes a unique prodrug delivery mechanism to concentrate the potent tubulin disruptor monomethyl auristatin E (MMAE) selectively within...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,228,594.00 to the Regents of the University of California, San Francisco (UCSF) for research on bispecific antibody-drug conjugates against emerging targets in metastatic lethal prostate cancer. The award period is from April 15, 2024 to April 14, 2027. As a leading academic medical center and research institution, UCSF will leverage its...
The National Cancer Institute (NCI) awarded a $696,447 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Rector & Visitors of the University of Virginia to develop and evaluate a 203Pb/212Pb isotope-based SPECT imaging and targeted alpha therapy as precision therapeutic tools for mesothelioma. The project aims to target a tumor-selective CD46 epitope expressed across all major mesothelioma subtypes using a novel human monoclonal antibody. The research will assess...